Please select the option that best describes you:

When do you add an adjuvant bone-modifying agent in patients with history of localized breast cancer?  

Is there any role for denosumab? How do you counsel patients regarding the benefit of bisphosphonates on breast cancer outcomes?



Answer from: Medical Oncologist at Academic Institution
Comments
Medical Oncologist at East Carolina University
For lower risk patients (node-negative), do you ty...
Medical Oncologist at Icahn School of Medicine at Mount Sinai
I would consider any patient with a high FRAX and ...
Sign in or Register to read more

Answer from: Medical Oncologist at Academic Institution
Sign in or Register to read more

Answer from: Medical Oncologist at Academic Institution
Comments
Medical Oncologist at Valley Med Onc
As an aside, I try to give the first dose of ZA wi...
Medical Oncologist at Alvin & Lois Lapidus Cancer Institute Northwest Hospital
There are several schedules of zoledronic acid rep...
Medical Oncologist at University of Pittsburgh School of Medicine
I tend to use ZA IV q6m. There are fewer side effe...
Sign in or Register to read more